Smartphone-Based Control System for Type 1 Diabetes
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new diabetes management system that uses a modified insulin pump, a continuous glucose monitor (CGM), and a smartphone app. Researchers aim to determine if this system can better control blood sugar levels in children with type 1 diabetes. Participants will try different approaches, including maintaining glucose levels at normal or tight goals, with usual care periods before and after. Ideal candidates are children aged 6-13 who have used an insulin pump and a Dexcom CGM for at least three months and have had type 1 diabetes for over a year. As an unphased trial, this study offers a unique opportunity to contribute to innovative diabetes care solutions for children.
Do I have to stop taking my current medications for the trial?
The trial requires that you do not start any new non-insulin glucose-lowering medications during the study. If you are already on a stable dose of such a medication, you may continue it. However, you cannot use SGLT-2 or SGLT-1/2 inhibitors.
What prior data suggests that the AIDANET algorithm and its components are safe?
Research has shown that the AIDANET system is generally safe for managing blood sugar levels, whether aiming for normal or tight control. A small initial study with six participants found that the system safely managed their blood sugar, but more research with a larger group is needed to confirm these results.
Another study found that the AIDANET system can function without users needing to announce meals, which benefits people with Type 1 Diabetes. This feature aims to make the system easier to use.
Overall, early findings suggest the system is well-tolerated, but more data is needed for confirmation. For those considering joining a trial with this system, early research indicates it is likely safe.12345Why are researchers excited about this trial?
Researchers are excited about the AIDANET Pediatrics trial because it explores a novel approach to managing blood sugar in children with diabetes. Unlike standard treatments that often rely on manual monitoring and insulin injections, the AIDANET system is an automated method designed to maintain more precise glycemic control. It tests two different glycemia goals—normal and tight—potentially offering more tailored and effective management of blood sugar levels. This trial could lead to advancements in pediatric diabetes care by enhancing safety and optimizing glucose control, which are crucial for long-term health outcomes.
What evidence suggests that the AIDANET system with smartphone control, insulin pump, and CGM could be effective for glycemia management?
Research has shown that the AIDANET system can improve blood sugar control. In one study, participants using the system had an average blood sugar level of 161.3 mg/dL, compared to 168 mg/dL with their usual care, indicating better overall management. Another study found that automated insulin delivery systems, like AIDANET, help maintain blood sugar levels within a healthy range more frequently. In this trial, participants will use the AIDANET system with either a Normal Glycemia Goal or a Tight Glycemia Goal, both of which have demonstrated positive results in previous studies. These findings suggest the system may effectively manage blood sugar levels in people with diabetes.12567
Who Is on the Research Team?
Mark DeBoer, MD
Principal Investigator
University of Virginia Center for Diabetes Technology
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Usual Care Control Period
Participants complete two weeks of usual care before using the AIDANET system
AIDANET System Usage
Participants use the AIDANET system with either Normal or Tight Glycemia Goal
Usual Care Control Period
Participants complete two weeks of usual care after using the AIDANET system
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Tandem insulin system
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
Participants will complete two weeks Usual Care Control Period before the use of the AIDANET system, with system employing Tight Glycemia Goal.
Participants will complete two weeks Usual Care Control Period before the use of the AIDANET system, with system employing Normal Glycemia Goal.
Participants will complete two weeks Usual Care Control Period after the use of the AIDANET system, with system employing Tight Glycemia Goal.
Participants will complete two weeks Usual Care Control Period after the use of the AIDANET system, with system employing Normal Glycemia Goal.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mark D. DeBoer, MD, MSc., MCR
Lead Sponsor
Tandem Diabetes Care, Inc.
Industry Sponsor
DexCom, Inc.
Industry Sponsor
Kevin Sayer
DexCom, Inc.
Chief Executive Officer since 2015
Bachelor’s and Master’s degrees in Accounting and Information Systems from Brigham Young University
Dr. Shelly Lane
DexCom, Inc.
Chief Medical Officer since 2023
MD from University of California, San Diego
Citations
A Pilot Study Featuring Flexible Meal Announcement Options
The mean glucose during usual care was 168 ± 24.3 mg/dL, compared to 161.3 ± 16.7 mg/dL using the AIDANET system. Time-in-range (TIR) 70 to 180 ...
Safety and Feasibility of a Machine-Learning Bolus Priming ...
This is a research study about the UVA Automated Insulin Delivery System known as Adaptive NETwork (AIDANET). This system consists of a Reinforcement Learning ...
Study Details | NCT07039617 | AIDANET At Home Study
A randomized cross-over trial assessing glycemic control on Automated insulin delivery as Adaptive Network (AIDANET) algorithm when used in three modes: ...
Efficacy of automated insulin delivery systems in people with ...
The results showed that AID systems were beneficial to varying degrees with respect to the percentage of time in the range of 70–180 mg/dl and ...
User Experiences of a Bihormonal Fully Closed-Loop ...
AHCL system in adults significantly improves glycemic outcomes. This improved glycemic control was maintained over the 12 months. Switching ...
6.
diabetesjournals.org
diabetesjournals.org/diabetes/article/74/Supplement_1/962-P/159109/962-P-Evaluating-Type-1-Diabetes-T1D-Care-across962-P: Evaluating Type 1 Diabetes (T1D) Care across All ...
The AIDANET system uses an adaptive algorithm that removes the need for meal announcement. This may help address age-specific obstacles in T1D.
AIDANET Pediatrics - UCSF Diabetes Trial
This study aims to demonstrate the safety and feasibility of the Automated insulin delivery as Adaptive NETwork (AIDANET) system among children age 6-13 ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.